Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (Diluted Average): 2021-2024

Historic Shares Outstanding (Diluted Average) for Janux Therapeutics (JANX) over the last 4 years, with Dec 2024 value amounting to $53.8 million.

  • Janux Therapeutics' Shares Outstanding (Diluted Average) rose 13.54% to $62.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.0 million, marking a year-over-year increase of 13.54%. This contributed to the annual value of $53.8 million for FY2024, which is 22.12% up from last year.
  • Per Janux Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $53.8 million for FY2024, which was up 22.12% from $44.0 million recorded in FY2023.
  • Janux Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $53.8 million for FY2024, and its period low was $23.5 million during FY2021.
  • Over the past 3 years, Janux Therapeutics' median Shares Outstanding (Diluted Average) value was $44.0 million (recorded in 2023), while the average stood at $46.4 million.
  • Data for Janux Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 76.24% (in 2022) over the last 5 years.
  • Over the past 4 years, Janux Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $23.5 million in 2021, then surged by 76.24% to $41.5 million in 2022, then climbed by 6.14% to $44.0 million in 2023, then climbed by 22.12% to $53.8 million in 2024.